ACAD vs HSIC · P/E 15, rev $576.0M vs P/E 24, rev $6.83B
ACADIA Pharmaceuticals Inc (ACAD) versus Henry Schein Inc (HSIC) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported HSIC revenue for 2026-06-27 was $6.83B. Net income was $201.0M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Not investment advice. Open the ACAD and HSIC stock pages for the full models.
Not investment advice.